NCT05664971 2025-12-02
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Completed
Clinical Trials
18 trialsNCT05000684 2025-02-20
Study of JS004 Combined With Toripalimab for Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Completed
NCT05021328 2025-02-07
Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC
Hubei Cancer Hospital
Phase 1 Completed
NCT04518280 2025-01-17
TORCH
Fudan University
Phase 2 Completed
NCT06618014 2025-01-16
NeoTOP
Sun Yat-sen University
Phase 2 Completed
NCT04996758 2024-12-12
Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)
Sun Yat-sen University
Phase 2 Completed
NCT05060471 2024-12-03
PD-1 Blockade Combined with Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients
Sun Yat-sen University
Phase 2 Completed
NCT03874897 2024-04-30
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Peking University
Phase 1 Completed
NCT04627012 2024-03-06
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Completed
NCT04238169 2024-02-28
Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC
Xinqiao Hospital of Chongqing
Phase 2 Completed
NCT04473716 2023-11-22
Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients
Shanghai Jiao Tong University School of Medicine
Phase 1 Completed
NCT04217954 2023-06-23
HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC
Peking University
Phase 2 Completed
NCT04044313 2023-06-12
HAIC Plus Lenvatinib and Toripalimab for Advanced HCC
Sun Yat-sen University
Phase 2 Completed
NCT05809336 2023-04-12
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital
Phase 2/3 Completed
NCT03732664 2023-03-24
ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Completed
NCT03856411 2023-02-01
A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Completed
NCT04005170 2022-08-23
Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer
Sun Yat-sen University
Phase 2 Completed
NCT03316144 2020-09-30
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Completed